489 related articles for article (PubMed ID: 27510924)
21. Methylated circulating tumor DNA in blood: power in cancer prognosis and response.
Warton K; Mahon KL; Samimi G
Endocr Relat Cancer; 2016 Mar; 23(3):R157-71. PubMed ID: 26764421
[TBL] [Abstract][Full Text] [Related]
22. Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer.
Kioulafa M; Balkouranidou I; Sotiropoulou G; Kaklamanis L; Mavroudis D; Georgoulias V; Lianidou ES
Int J Cancer; 2009 Dec; 125(12):2887-92. PubMed ID: 19551853
[TBL] [Abstract][Full Text] [Related]
23. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay.
Markou A; Strati A; Malamos N; Georgoulias V; Lianidou ES
Clin Chem; 2011 Mar; 57(3):421-30. PubMed ID: 21245367
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer.
Stergiopoulou D; Markou A; Strati A; Zavridou M; Tzanikou E; Mastoraki S; Kallergi G; Georgoulias V; Lianidou E
Sci Rep; 2023 Jan; 13(1):1258. PubMed ID: 36690653
[TBL] [Abstract][Full Text] [Related]
25. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival.
Balgkouranidou I; Karayiannakis A; Matthaios D; Bolanaki H; Tripsianis G; Tentes AA; Lianidou E; Chatzaki E; Fiska A; Lambropoulou M; Kolios G; Kakolyris S
Clin Chem Lab Med; 2013 Jul; 51(7):1505-10. PubMed ID: 23403728
[TBL] [Abstract][Full Text] [Related]
26. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
Chen X; Wang L; Lou J
Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
[TBL] [Abstract][Full Text] [Related]
27. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.
Gold B; Cankovic M; Furtado LV; Meier F; Gocke CD
J Mol Diagn; 2015 May; 17(3):209-24. PubMed ID: 25908243
[TBL] [Abstract][Full Text] [Related]
28. Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.
Rivenbark AG; Livasy CA; Boyd CE; Keppler D; Coleman WB
Exp Mol Pathol; 2007 Oct; 83(2):188-97. PubMed ID: 17540367
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer.
Takai E; Yachida S
World J Gastroenterol; 2016 Oct; 22(38):8480-8488. PubMed ID: 27784960
[TBL] [Abstract][Full Text] [Related]
30. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer.
De Mattos-Arruda L; Caldas C
Mol Oncol; 2016 Mar; 10(3):464-74. PubMed ID: 26776681
[TBL] [Abstract][Full Text] [Related]
31. Multigene methylation analysis of enriched circulating tumor cells associates with poor progression-free survival in metastatic breast cancer patients.
Benezeder T; Tiran V; Treitler AAN; Suppan C; Rossmann C; Stoeger H; Cote RJ; Datar RH; Balic M; Dandachi N
Oncotarget; 2017 Nov; 8(54):92483-92496. PubMed ID: 29190932
[TBL] [Abstract][Full Text] [Related]
32. A network-based approach to identify disease-associated gene modules through integrating DNA methylation and gene expression.
Zhang Y; Zhang J; Liu Z; Liu Y; Tuo S
Biochem Biophys Res Commun; 2015 Sep; 465(3):437-42. PubMed ID: 26282201
[TBL] [Abstract][Full Text] [Related]
33. Correlation of Methylated Circulating Tumor DNA With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
Takahashi H; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Clin Breast Cancer; 2017 Feb; 17(1):61-69.e3. PubMed ID: 27395416
[TBL] [Abstract][Full Text] [Related]
34. Liquid Biopsy for the Management of Patients with Colorectal Cancer.
Yamada T; Matsuda A; Koizumi M; Shinji S; Takahashi G; Iwai T; Takeda K; Ueda K; Yokoyama Y; Hara K; Hotta M; Matsumoto S; Yoshida H
Digestion; 2019; 99(1):39-45. PubMed ID: 30554222
[TBL] [Abstract][Full Text] [Related]
35. Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients.
Li Z; Guo X; Wu Y; Li S; Yan J; Peng L; Xiao Z; Wang S; Deng Z; Dai L; Yi W; Xia K; Tang L; Wang J
Breast Cancer Res Treat; 2015 Feb; 149(3):767-79. PubMed ID: 25636590
[TBL] [Abstract][Full Text] [Related]
36. Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook.
Lianidou E
Mol Oncol; 2021 Jun; 15(6):1683-1700. PubMed ID: 33942482
[TBL] [Abstract][Full Text] [Related]
37. Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
Visvanathan K; Fackler MS; Zhang Z; Lopez-Bujanda ZA; Jeter SC; Sokoll LJ; Garrett-Mayer E; Cope LM; Umbricht CB; Euhus DM; Forero A; Storniolo AM; Nanda R; Lin NU; Carey LA; Ingle JN; Sukumar S; Wolff AC
J Clin Oncol; 2017 Mar; 35(7):751-758. PubMed ID: 27870562
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic cancer: Are "liquid biopsies" ready for prime-time?
Lewis AR; Valle JW; McNamara MG
World J Gastroenterol; 2016 Aug; 22(32):7175-85. PubMed ID: 27621566
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression.
Ai L; Kim WJ; Kim TY; Fields CR; Massoll NA; Robertson KD; Brown KD
Cancer Res; 2006 Aug; 66(16):7899-909. PubMed ID: 16912163
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays.
Rodenhiser DI; Andrews J; Kennette W; Sadikovic B; Mendlowitz A; Tuck AB; Chambers AF
Breast Cancer Res; 2008; 10(4):R62. PubMed ID: 18638373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
